ArticleMicrobial cell factories2016
Engineering Escherichia coli to convert acetic acid to β-caryophyllene.
Article in Microbial cell factories, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 54 citations in OpenAlex.
- Highly efficient production ofSynthetic and systems biotechnology · 2027Article
- Headspace Volatile Profile of Fresh-Cut Broccoli Raab in PET Packaging as Affected by Microperforation.Foods (Basel, Switzerland) · 2025Article
- Short-Chain Fatty Acid Utilization inMicroorganisms · 2025Article
- Efficient biosynthesis of β-caryophyllene by engineered Yarrowia lipolytica.Microbial cell factories · 2025Article
- Efficient biosynthesis ofSynthetic and systems biotechnology · 2025Article
- Application of Acetate as a Substrate for the Production of Value-Added Chemicals inMicroorganisms · 2024Review
- Perspectives for Using COBioengineering (Basel, Switzerland) · 2023Review
- Tandem expression of Ganoderma sinense sesquiterpene synthase and IDI promotes the production of gleenol in E. coli.Applied microbiology and biotechnology · 2022Article
- Metabolic engineering using acetate as a promising building block for the production of bio-based chemicals.Engineering microbiology · 2022Review
- Enhancing fluxes through the mevalonate pathway in Saccharomyces cerevisiae by engineering the HMGR and β-alanine metabolism.Microbial biotechnology · 2022Article
- Highly efficient biosynthesis of β-caryophyllene with a new sesquiterpene synthase from tobacco.Biotechnology for biofuels and bioproducts · 2022Article
- Microbial Utilization of Next-Generation Feedstocks for the Biomanufacturing of Value-Added Chemicals and Food Ingredients.Frontiers in bioengineering and biotechnology · 2022Review
- Physiological limitations and opportunities in microbial metabolic engineering.Nature reviews. Microbiology · 2022Review
- Rationally optimized generation of integratedSynthetic and systems biotechnology · 2021Article
- Adaptive laboratory evolution of β-caryophyllene producing Saccharomyces cerevisiae.Microbial cell factories · 2021Article
- Heterologous Production of β-Caryophyllene and Evaluation of Its Activity against Plant Pathogenic Fungi.Microorganisms · 2021Article
- Acetate Kinase a Antisense Delivery by PAMAM Dendrimer for Decreasing Acetate Production and Increasing the Production of Recombinant Albumin inIranian journal of biotechnology · 2021Article
- Microbial Upgrading of Acetate into Value-Added Products-Examining Microbial Diversity, Bioenergetic Constraints and Metabolic Engineering Approaches.International journal of molecular sciences · 2020Review
- Article
- Esterification of geraniol as a strategy for increasing product titre and specificity in engineered Escherichia coli.Microbial cell factories · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnder aerobic conditions, acetic acid is the major byproduct produced by E. coli during the fermentation. And acetic acid is detrimental to cell growth as it destroys transmembrane pH gradients. Hence, how to reduce the production of acetic acid and how to utilize it as a feedstock are of intriguing interest. In this study, we provided an evidence to produce β-caryophyllene by the engineered E. coli using acetic acid as the only carbon source.
resultsFirstly, to construct the robust acetate-utilizing strain, acetyl-CoA synthases from three different sources were introduced and screened in the E. coli. Secondly, to establish the engineered strains converting acetic acid to β-caryophyllene, acetyl-CoA synthase (ACS), β-caryophyllene synthase (QHS1) and geranyl diphosphate synthase (GPPS2) were co-expressed in the E. coli cells. Thirdly, to further enhance β-caryophyllene production from acetic acid, the heterologous MVA pathway was introduced into the cells. What's more, acetoacetyl-CoA synthase (AACS) was also expressed in the cells to increase the precursor acetoacetyl-CoA and accordingly resulted in the increase of β-caryophyllene. The final genetically modified strain, YJM67, could accumulate the production of biomass and β-caryophyllene up to 12.6 and 1.05 g/L during 72 h, respectively, with a specific productivity of 1.15 mg h(-1) g(-1) dry cells, and the conversion efficiency of acetic acid to β-caryophyllene (gram to gram) reached 2.1%. The yield of β-caryophyllene on acetic acid of this strain also reached approximately 5.6% of the theoretical yield.
conclusionsIn the present study, a novel biosynthetic pathway for β-caryophyllene has been investigated by means of conversion of acetic acid to β-caryophyllene using an engineered Escherichia coli. This was the first successful attempt in β-caryophyllene production by E. coli using acetic acid as the only carbon source. Therefore, we have provided a new metabolic engineering tool for β-caryophyllene synthesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.